Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Results Preview: Amgen, the juggler

This article was originally published in Scrip

Executive Summary

Big biotech Amgen follows Johnson & Johnson into the reporting box on Wednesday 23rd January. Like J&J which reported its annual results on 22 January, Amgen shares with Lance Armstrong an interest in ESAs. Unlike the cyclist, they still have a lot riding on EPOs, and for Amgen they represent more than a fifth of the revenue base. Nevertheless, the firm has a number of other fish to fry as it manages the slow decline of its Aranesp (darbepoetin alfa)/Epogen (epoetin alfa) business, and it was confident enough at the end of the fourth quarter to raise its full-year group revenue guidance from $16.9-17.2 billion to $17.2-17.3 billion.

Topics

Related Companies

UsernamePublicRestriction

Register

SC020127

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel